Kompass Diagnostics

Kompass Diagnostics

Kompass Diagnostics aims to expand healthcare beyond walls to shape new workflows that reduce healthcare costs, alleviate capacity shortages, and improve access to care. Kompass Diagnostics was founded by veterans in diagnostic commercialization, experts in semiconductor research, and entrepreneurs from Stanford University, the University of Chicago, and UCLA, with a vision to build a novel transduction platform that pioneers the next generation of point-of-care diagnostics. Its technology is the first multimodal diagnostic platform capable of delivering clinical-grade biochemistry, immunoassay, and molecular diagnostics in a single palm-sized device. Its proprietary electrical transduction assay (ETA) platform exhibits analytical sensitivity comparable to state-of-the-art laboratory technologies, enabling a broad menu of tests across diverse point-of-care settings based on finger-prick whole blood analysis within 10 minutes. The company’s first test is a rapid, multi-hormone test that guides time-sensitive decisions in fertility treatments like in vitro fertilization and egg freezing, reducing turnaround from hours to ten minutes. By increasing clinic capacity to serve more patients and reducing the operational costs of clinics, Kompass allows clinics to scale with a rapidly increasing demand for fertility treatments.

Is this you? Claim this profile →